The Commerce Department said the economy barely grew in the first quarter, with the nation's gross domestic product rising at a 0.1% annual pace. That's down from 2.6% growth in the fourth quarter and the weakest since late 2012.
Striking a more positive note, payroll processor ADP said businesses added 220,000 jobs in April, more than the median estimate of 200,000 in a survey by Action Economics. The economists surveyed also estimate that Friday's more closely watched employment report will show that the public and private sectors added a total 210,000 jobs last month, the most since last fall.
Best Net Payout Yield Companies To Watch In Right Now: Lucara Diamond Corp (LUCRF.PK)
Lucara Diamond Corp. (Lucara) is a diamond development company focused in Africa. The business of Lucara consists of the acquisition, exploration and development of diamond properties. The principal assets of Lucara and the focus of Lucara�� development and exploration activities are its interest in mining, exploration and prospecting diamond licenses in Lesotho, Botswana and Namibia. The Company�� project Mothae Diamond Project is located in northeast Lesotho. In May 2010, it commenced test mining in Mothae Diamond Project-Lesotho. Mothae Diamonds (PTY) Ltd (Mothae Diamonds), an indirect 75% owned subsidiary of the Company, holds a 100% interest in the Mothae project. As of March 23, 2011, a total of 175,000 dry tons had been processed from the C domain, producing 5,484 carats at an average grade of 3.13 carats per hundred tons. In December 2010, the Company completed the acquisition of African Diamonds PLC, upon which Lucara indirectly owns 100% of the AK6 Diamond Project. Advisors' Opinion:- [By John Leonard]
Lucara Diamond (LUCRF.PK) is still being valued as a riskier exploration stage miner rather than a profitable and growing producer. The current "backward looking" valuation fails to reflect the recent and significant operational transition.
Top 10 Rising Stocks To Own Right Now: RadNet Inc.(RDNT)
RadNet, Inc. provides outpatient diagnostic imaging services in the United States. The company offers various imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures. It also provides teleradiology services to radiology groups, hospitals, and imaging centers. In addition, the company offers picture archiving and communications systems and related workflow solutions for hospitals, teleradiology businesses, imaging centers, and specialty physician groups to distribute, visualize, store, and retrieve digital images taken from various diagnostic imaging modalities. As of December 31, 2011, it operated 233 diagnostic imaging facilities in California, Delaware, Maryland, New Jersey, Rhode Island, Florida, and New York. RadNet, Inc. was founded in 1985 and is headquartered in Los Angeles, California.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Alamy There are plenty of stocks going up -- and down -- in any given week. The gainers inspire us to keep investing. The decliners keep greed in check while reminding us about the risks of the equity markets. Let's go over some of last week's best and worst performers. Pike (PIKE) -- Up 49 percent last week The market's biggest winner of last week was Pike, a specialty construction and engineering firm that received a bid to be taken private. J. Eric Pike -- the firm's chairman and CEO -- is teaming up with private equity firm Court Square Capital Partners to buy out shareholders at $12 a share. It's a fair premium, pricing the buyout at a better than 50 percent premium to where the stock was trading when it was announced. A few attorneys are trying to smoke out investors who feel that the CEO-led privatization push isn't fair, but it's likely to stick at that kind of healthy markup. Pike shares may have traded in the low teens last summer, but that was before revenue and earnings began heading the wrong way. Most shareholders should be more than happy to take the money and run. RadNet (RDNT) -- Up 34 percent last week Operating a network of 251 facilities that perform outpatient diagnostic imaging services is looking good for RadNet. The stock moved sharply higher after a strong quarterly report. Revenue inched slighting higher as MRI and CT scan volume increased modestly during the period. However, the real star in the report was RadNet's bottom line. Its cost-cutting and debt-slashing efforts paid off with net income soaring to $0.12 a share after clocking in at a $0.07 a share a year earlier. Analysts were only holding out for $0.05 a share. RadNet also helped improve its standing by boosting its guidance for all of 2014. You don't need any of RadNet's fancy imaging equipment to see that that's a healthy sign. Trex (TREX) -- Up 25 percent last week It was a good week for a pair of home improvement specialists. Shares of CaesarStone (CSTE) moved 20
Top 10 Rising Stocks To Own Right Now: SciClone Pharmaceuticals Inc.(SCLN)
SciClone Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People?s Republic of China and internationally. Its principal product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, primarily China, the Pacific Rim, Latin America, eastern Europe, and the Middle East. The company markets and sells ZADAXIN principally through its distributors. It is also developing SCV-07, which is in Phase 2 clinical trials for the treatment of oral mucositis and hepatitis C virus. In addition, the company markets partnered products in China, including Depakine, an anti-convulsant; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia; and Aggrastat, a cardiology product. SciClone Pharmaceuticals also has commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam. The company was founded in 1989 and is headquartered in Foster City, California.
Advisors' Opinion:- [By Monica Gerson]
SciClone Pharmaceuticals (NASDAQ: SCLN) is expected to report its Q4 earnings at $0.15 per share on revenue of $38.30 million.
Essex Rental (NASDAQ: ESSX) is projected to post a Q4 loss at $0.10 per share on revenue of $22.55 million.
- [By Eric Volkman]
SciClone (NASDAQ: SCLN ) has a new man leading its finance team. The company announced that it hired Wilson Cheung to be its new CFO. Cheung is a longtime executive who most recently served as chief compliance officer, Asia Pacific, at digital marketing agency Velti, following a stint as that company's CFO. Before that, he was CFO and corporate secretary at AXT (NASDAQ: AXTI ) and served in various managerial positions in firms such as KPMG and Yahoo!
Top 10 Rising Stocks To Own Right Now: Cloud Peak Energy Inc(CLD)
Cloud Peak Energy Inc., through its subsidiaries, engages in coal mining operations in the Powder River Basin of the United States. It produces sub-bituminous steam coal with low sulfur content for electric utilities and industrial customers. The company owns and operates Antelope surface coal mine located to the south of Gillette, Wyoming; the Cordero Rojo surface coal mine located to the south of Gillette, Wyoming; and the Spring Creek surface coal mine located in Montana. It also owns a 50% interest in the Decker surface coal mine located in Montana. As of December 31, 2010, it had approximately 970 million tons of proven and probable reserves. The company was founded in 1993 and is headquartered in Gillette, Wyoming.
Advisors' Opinion:- [By Ben Levisohn]
Cloud Peak Energy (CLD) has gained 3.1% to %15.03 after it was upgraded to Buy from Hold at Stifel.
Novatris (NVS) has dropped 1.2% to $74.48 after it was downgraded to Neutral from Overweight at JP Morgan.
Top 10 Rising Stocks To Own Right Now: ZELTIQ Aesthetics Inc (ZLTQ)
ZELTIQ Aesthetics, Inc. (ZELTIQ), incorporated on March 22, 2005, is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ�� North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ�� physician customers.
CoolSculpting System
ZELTIQ generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. Capital sales of ZELTIQ�� CoolSculpting System include the CoolSculpting control unit and its CoolSculpting vacuum applicators. ZELTIQ generates procedure fees through sales of CoolSculpting procedure packs, which include its consumable gelpads and liners and a disposable computer cartridge that it markets as the CoolCard. The CoolCard contains enabling software that permits its physician customer to perform a fixed number of CoolSculpting procedures.
The CoolSculpting control unit is the base of the CoolSculpting System. ZELTIQ�� CoolSculpting control unit also contains software that tracks and collects data about each procedure performed and any error messages that may be generated during the procedure. CoolSculpting System includes three CoolSculpting vacuum applicators. ZELTIQ�� CoolSculpting procedure packs facilitate the pay-per-procedu! re feature of its CoolSculpting System. Its CoolSculpting procedure packs include CoolCard and its consumable gelpads and liners.
Advisors' Opinion:- [By Garrett Cook]
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from ZELTIQ Aesthetics (NASDAQ: ZLTQ) and Aegerion Pharmaceuticals (NASDAQ: AEGR).
- [By John Udovich]
On Tuesday, small cap biotech stock Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) surged around 25% after announcing that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints for the reduction of so-called double chins; but if investors missed out on that rally, small caps Zeltiq Aesthetics Inc (NASDAQ: ZLTQ), Solta Medical Inc (NASDAQ: SLTM) and Cynosure, Inc (NASDAQ: CYNO) each have a piece of the aesthetic market as well. In the case of Kythera Biopharmaceuticals, its ATX-101 can be injected to deal with double chins���meaning its less invasive than liposuction as the drug dissolves fat cells but leaves other tissue alone. JP Morgan has noted:
Top 10 Rising Stocks To Own Right Now: Wells Fargo Advantage Income Opportunities Fund (EAD)
Evergreen Income Advantage Fund (the Fund) is a diversified closed-end management investment company. The primary investment objective of the Fund is to seek a high level of current income.
During the fiscal year ended April 30, 2005, the Fund's investment portfolio included Marquee Holdings, Inc., Mediacom LLC, American Achievement Corp., CSK Auto, Inc., Oxford Industries, Inc., B&G Foods Holdings Corp. and Chiquita Brands International, Inc.
Advisors' Opinion:- [By Namitha Jagadeesh]
European Aeronautic, Defence & Space Co. (EAD) rose 1.8 percent to 47.28 euros, the highest price since it sold shares to the public in 2000. Deutsche Lufthansa AG split an order for 59 wide-body aircraft valued at $19 billion between EADS unit Airbus SAS and Boeing Co.
- [By Inyoung Hwang]
EADS (EAD) declined 1.2 percent to 51.54 euros. UBS said in a note that investing in the company is ��ess compelling��after shares rallied 77 percent in 2013 through yesterday and orders were announced following the Dubai Air Show.
- [By Sarah Jones]
Daimler AG jumped 6.2 percent to 52.35 euros. The world�� third-largest maker of luxury cars posted second-quarter profit that beat analyst predictions following the sale of its final holding in the parent company of planemaker Airbus SAS. (EAD)
- [By Jim Jubak]
Precision Castparts' impressive growth in the June quarter was largely a result of acquisitions. Organic sales growth year over year came to just 2%. Most of the time I don't like growth stocks that are fueled by acquisition since these deals can hide the true (frequently negative) trend in core sales and earnings growth. But in the case of Precision Castparts, an acquisition strategy makes sense to me, because it is a reflection of what's going on in the aerospace sector. Companies like Boeing (BA) and Airbus (EAD) are looking to simplify their supply chain and to deal with fewer suppliers. Rolling up part of the supply chain under one roof, which is what Precision Castparts is doing right now, is a way to gain a bigger share of the business of these big end customers.
Top 10 Rising Stocks To Own Right Now: Nuveen Preferred and Convertible Income Fund (JPC)
Nuveen Multi-Strategy Income & Growth Fund is a close-ended balanced mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Asset Management, Spectrum Asset Management, Tradewinds Global Investors, LLC, and Symphony Asset Management, LLC. It invests in the public equity and fixed income markets of the United States. The fund seeks to invest in the stocks of companies operating across diversified sectors. For the fixed income portfolio, it invests in the debt instruments, including high yield debt and senior loans. The fund benchmarks the performance of its portfolio against the Merrill Lynch Preferred Stock Hybrid Securities Index, Lehman Tier 1 Capital Securities Index, Merrill Lynch All U.S. Convertibles Index, and CSFB High Yield index. It was formerly known as Nuveen Preferred and Convertible Income Fund. Nuveen Multi-Strategy Income & Growth Fund was formed on March 26, 2003 and is domiciled in the United States.
Advisors' Opinion:- [By Douglas A. McIntyre]
J.C. Penney (NYSE: JPC) and the KMart and Sears divisions of Sears Holdings (NASDAQ: SHLD) are supposes to be the losers among large U.S. retailers. Their stores are too old, their brands too badly damaged, and their balance sheet too frail for either to do well in the white hot competition for holiday sales. However, their stock prices say otherwise, which means there is some expectation that they will outperform forecasts.
No comments:
Post a Comment